Eli Lilly and Company (LLY)vsWORK Medical Technology Group LTD Ordinary Shares (WOK)
LLY
Eli Lilly and Company
$1,131.42
-2.41%
HEALTHCARE · Cap: $948.95B
WOK
WORK Medical Technology Group LTD Ordinary Shares
$0.09
-15.70%
HEALTHCARE · Cap: $118,580
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 733489% more annual revenue ($72.25B vs $9.85M). LLY leads profitability with a 35.0% profit margin vs -10.9%. LLY earns a higher WallStSmart Score of 78/100 (B+).
LLY
Strong Buy78
out of 100
Grade: B+
WOK
Avoid35
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 81 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.9% YoY
Reasonable price relative to book value
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 32.4x book value
Grey zone — moderate risk
Smaller company, higher risk/reward
ROE of -5.8% — below average capital efficiency
Revenue declined 14.4%
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bull Case : WOK
The strongest argument for WOK centers on Price/Book.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book.
Bear Case : WOK
The primary concerns for WOK are Altman Z-Score, Market Cap, Return on Equity.
Key Dynamics to Monitor
LLY profiles as a growth stock while WOK is a turnaround play — different risk/reward profiles.
LLY is growing revenue faster at 55.5% — sustainability is the question.
LLY generates stronger free cash flow (3.0B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
LLY scores higher overall (78/100 vs 35/100), backed by strong 35.0% margins and 55.5% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →WORK Medical Technology Group LTD Ordinary Shares
HEALTHCARE · MEDICAL DEVICES · USA
WORK Medical Technology Group Ltd is a prominent player in the medical technology sector, focusing on the research, development, and commercialization of innovative healthcare solutions. With a strong emphasis on advanced medical devices, the company strives to improve patient outcomes and tackle significant challenges in global healthcare. Its dedication to quality, innovation, and a diverse product portfolio not only enhances its market position but also aligns with the interests of institutional investors seeking opportunities in transformative healthcare advancements. As the demand for effective medical technologies continues to rise, WORK is well-positioned for sustained growth and value creation.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?